Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cytodyn Inc

Healthcare US CYDY

0.2848USD
-0.0052(1.79%)

Last update at 2026-06-15T19:56:00Z

Day Range

0.270.29
LowHigh

52 Week Range

0.200.45
LowHigh

Fundamentals

  • Previous Close 0.29
  • Market Cap510.90M
  • Volume934115
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.39800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -20.63300M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Income before tax 3.75M -49.84100M -79.82400M -210.82000M -154.67400M
Minority interest - - - - -
Net income 3.75M -49.84100M -79.82400M -210.82000M -154.67400M
Selling general administrative 7.26M 10.82M 17.14M 44.30M 34.32M
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 0.00000M 0.21M -4.38700M
Reconciled depreciation 0.02M 0.03M 0.17M 0.78M 1.80M
Ebit - - -40.57600M -145.40400M -139.65900M
Ebitda - - - -157.59200M -133.38600M
Depreciation and amortization - - - - -
Non operating income net other - - - - -35.06300M
Operating income 9.66M -18.05800M -40.57600M -145.40400M -104.59600M
Other operating expenses - - - 0.78M 1.80M
Interest expense 4.83M 5.74M 6.75M 52.45M 19.34M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.56M 0.22M - - 0.00200M
Net interest income -5.47100M -18.17300M -30.49800M -61.56300M -19.55400M
Extraordinary items - - - - -
Non recurring - - - - 20.68M
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.27M -4.38700M
Total operating expenses -9.66100M 18.06M 40.58M 72.13M 115.22M
Cost of revenue - 0.00000M 0.00000M 73.54M -
Total other income expense net -0.44500M -13.61000M -8.75000M -77.34300M -40.57300M
Discontinued operations - - - - -
Net income from continuing ops 3.75M -49.84100M -79.82400M -210.82000M -154.67400M
Net income applicable to common shares - - -86.73600M -210.82000M -154.67400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Total assets 18.05M 11.14M 11.29M 29.18M 132.08M
Intangible assets - - - 0.13M 1.65M
Earning assets - - - - -
Other current assets - - 7.10M 6.28M 2.16M
Total liab 114.09M 127.89M 120.79M 123.58M 153.10M
Total stockholder equity -96.04200M -116.75800M -109.50100M -94.39800M -21.01800M
Deferred long term liab - - - - -
Other current liab 0.14M 0.03M 10.37M 8.99M 19.25M
Common stock - - 0.92M 0.72M 0.63M
Capital stock 1.25M 1.06M 0.92M 0.72M 0.63M
Retained earnings -887.78600M -891.53100M -841.69000M -766.13100M -511.29400M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.09M 17.93M 93.48M
Cash 11.90M 3.11M 2.54M 4.23M 33.94M
Cash and equivalents - - - - -
Total current liabilities 70.52M 84.18M 119.80M 123.16M 152.55M
Current deferred revenue - - - - -
Net debt 15.30M 26.68M 32.59M 32.01M 28.80M
Short term debt - - - 36.24M 62.75M
Short long term debt 27.20M 29.79M 34.42M 36.24M 62.75M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - 0.40M 0.07M 0.13M
Total current assets 17.88M 10.81M 10.80M 10.52M 129.58M
Long term investments - - - - -
Net tangible assets - - -109.50100M -94.53000M -22.67100M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - 0.71M - -
Inventory - - - 17.93M 93.48M
Accounts payable 14.69M 29.56M 62.73M 81.90M 73.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.72M 0.63M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -766.13100M -511.29400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.17M 0.32M 0.49M 0.54M 0.71M
Deferred long term asset charges - - - - -
Non current assets total 0.17M 0.32M 0.49M 0.74M 2.50M
Capital lease obligations 0.14M 0.28M 0.28M 0.56M 0.73M
Long term debt total - - - - -
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Investments 0.00000M 0.00000M 0.00000M 0.00000M -0.12200M
Change to liabilities - - -3.09700M -2.71300M 53.01M
Total cashflows from investing activities - - - - -0.12200M
Net borrowings -0.71000M 2.01M 0.90M 0.90M 99.05M
Total cash from financing activities 10.85M 11.75M 29.93M 48.01M 137.35M
Change to operating activities - - 1.90M -4.12500M 1.23M
Net income 3.75M -49.84100M -79.82400M -210.82000M -154.67400M
Change in cash 2.09M 0.77M 4.82M -29.71200M 19.65M
Begin period cash flow 9.81M 9.05M 4.23M 33.94M 14.29M
End period cash flow 11.90M 9.81M 9.05M 4.23M 33.94M
Total cash from operating activities -8.76500M -10.98200M -25.11000M -77.72300M -117.57300M
Issuance of capital stock 0.00000M 9.14M 25.79M 41.20M 1.00M
Depreciation 0.02M 0.03M 0.17M 3.83M 5.45M
Other cashflows from investing activities - - - - -
Dividends paid - - - 0.00000M 0.24M
Change to inventory - - 0.00000M 2.06M -74.33200M
Change to account receivables - - - - -
Sale purchase of stock - - - 42.62M 22.27M
Other cashflows from financing activities - - 2.81M 5.39M 16.27M
Change to netincome - - 43.86M 79.73M 51.74M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.12M
Change receivables - - - - -
Cash flows other operating - - - 50.20M 1.23M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -29.71200M 19.65M
Change in working capital -16.17200M 11.66M -1.19500M -4.77800M -20.09200M
Stock based compensation 1.61M 2.42M 4.28M 6.24M 10.43M
Other non cash items - 4.47M 16.76M 57.37M 15.02M
Free cash flow -8.76500M -10.98200M -25.11000M -77.72300M -117.69500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYDY
Cytodyn Inc		 -0.0052 1.79% 0.28 - 10.81 761.84 1066.03 1010.08 40.35
NVO
Novo Nordisk A/S		 0.04 0.09% 43.92 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.40 0.91% 44.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.54 1.24% 450.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.84 0.46% 614.98 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Cytodyn Inc

1111 Main Street, Vancouver, WA, United States, 98660

Key Executives

Name Title Year Born
Mr. Antonio Migliarese CPA CFO, Treasurer & Sec. 1983
Mr. Cyrus Arman M.B.A., Ph.D. Pres 1981
Dr. Bernie Cunningham P.M.P., Ph.D. VP of Operations NA
Mr. George Bitar Head of Quality & Exec. Director NA
Dr. Kush Dhody Sr. VP of Clinical Operations NA
Dr. Denis R. Burger Scientific Consultant 1944
Ms. Cristina De Leon Investors NA
Dr. Jacob P. Lalezari M.D. Chief Executive Officer 1960
Mr. Tyler Blok Chief Legal Officer & Corporate Secretary 1987
Dr. Bernie Cunningham P.M.P., Ph.D. Vice President of Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.